Blog Viewer

April Blog post, round 2: Ozempic 2mg

By Katelyn O'Brien posted 04-13-2022 10:03


FDA approves 2mg dose of Ozempic (semaglutide) for T2DM


0.25mg weekly x 4 weeks (to avoid GI side effects)

0.5mg weekly as maintenance dose, if tolerating after 4 weeks and need additional glucose control, may increase to 1mg weekly. After 4 weeks if tolerating, may increase to 2mg weekly.

Dosage forms:

2mg/1.5mL pen: 0.25mg or 0.5mg doses

4mg/3mL pen: 1mg doses

8mg/3mL pen: 2mg doses

Trial Data – SUSTAIN FORTE:Efficacy and Safety of once weekly semaglutide 2mg vs 1mg in patients with T2DM; double blind, randomized trial

In the SUSTAIN FORTE trial, people with an average starting A1C of 8.9% treated with Ozempic® 2 mg achieved a statistically significant and superior reduction in blood sugar of 2.1% at week 40 compared to 1.9% with Ozempic® 1 mg (P<0.01). Average starting weight of 219 lb treated with Ozempic® 2 mg experienced a weight loss of 14.1 lb compared to a weight loss of 12.5 lb with Ozempic® 1 mg; the difference was not statistically significant. For both doses of Ozempic®, there were no new safety signals identified. The most common adverse events were gastrointestinal. Gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic® 2 mg (34.0%) vs Ozempic® 1 mg (30.8%).

Does anyone already have patients in mind that they plan to titrate?